Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 218

1.

Predicting aggressive behavior in nonfunctioning pancreatic neuroendocrine tumors.

Cherenfant J, Stocker SJ, Gage MK, Du H, Thurow TA, Odeleye M, Schimpke SW, Kaul KL, Hall CR, Lamzabi I, Gattuso P, Winchester DJ, Marsh RW, Roggin KK, Bentrem DJ, Baker MS, Prinz RA, Talamonti MS.

Surgery. 2013 Oct;154(4):785-91; discussion 791-3. doi: 10.1016/j.surg.2013.07.004.

PMID:
24074416
2.

Population-level analysis of pancreatic neuroendocrine tumors 2 cm or less in size.

Kuo EJ, Salem RR.

Ann Surg Oncol. 2013 Sep;20(9):2815-21. doi: 10.1245/s10434-013-3005-7. Epub 2013 Jun 15.

PMID:
23771245
3.

Surgical experience with nonfunctioning neuroendocrine tumors of the pancreas.

Matthews BD, Heniford BT, Reardon PR, Brunicardi FC, Greene FL.

Am Surg. 2000 Dec;66(12):1116-22; discussion 1122-3.

PMID:
11149582
4.

Comparison of tumor markers for predicting outcomes after resection of nonfunctioning pancreatic neuroendocrine tumors.

Cherenfant J, Talamonti MS, Hall CR, Thurow TA, Gage MK, Stocker SJ, Lapin B, Wang E, Silverstein JC, Mangold K, Odeleye M, Kaul KL, Lamzabi I, Gattuso P, Winchester DJ, Marsh RW, Roggin KK, Bentrem DJ, Baker MS, Prinz RA.

Surgery. 2014 Dec;156(6):1504-10; discussion 1510-1. doi: 10.1016/j.surg.2014.08.043. Epub 2014 Nov 11.

PMID:
25456943
5.

Is laparoscopic resection adequate in patients with neuroendocrine pancreatic tumors?

Fernández-Cruz L, Blanco L, Cosa R, Rendón H.

World J Surg. 2008 May;32(5):904-17. doi: 10.1007/s00268-008-9467-2.

PMID:
18264824
6.

Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification.

Tsutsumi K, Ohtsuka T, Fujino M, Nakashima H, Aishima S, Ueda J, Takahata S, Nakamura M, Oda Y, Tanaka M.

J Hepatobiliary Pancreat Sci. 2014 Jun;21(6):418-25. doi: 10.1002/jhbp.47. Epub 2013 Oct 20.

PMID:
24142395
7.

Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients.

Bilimoria KY, Talamonti MS, Tomlinson JS, Stewart AK, Winchester DP, Ko CY, Bentrem DJ.

Ann Surg. 2008 Mar;247(3):490-500. doi: 10.1097/SLA.0b013e31815b9cae.

PMID:
18376195
8.

Resection of pancreatic neuroendocrine tumors: results of 70 cases.

Kazanjian KK, Reber HA, Hines OJ.

Arch Surg. 2006 Aug;141(8):765-9; discussion 769-70.

PMID:
16924083
9.

Implications of incidentally discovered, nonfunctioning pancreatic endocrine tumors: short-term and long-term patient outcomes.

Haynes AB, Deshpande V, Ingkakul T, Vagefi PA, Szymonifka J, Thayer SP, Ferrone CR, Wargo JA, Warshaw AL, Fernández-del Castillo C.

Arch Surg. 2011 May;146(5):534-8. doi: 10.1001/archsurg.2011.102.

10.

Analysis of lymph node metastasis in pancreatic neuroendocrine tumors (PNETs) based on the tumor size and hormonal production.

Tsutsumi K, Ohtsuka T, Mori Y, Fujino M, Yasui T, Aishima S, Takahata S, Nakamura M, Ito T, Tanaka M.

J Gastroenterol. 2012 Jun;47(6):678-85. doi: 10.1007/s00535-012-0540-0. Epub 2012 Feb 17.

PMID:
22350698
11.

Surgery and staging of pancreatic neuroendocrine tumors: a 14-year experience.

Ito H, Abramson M, Ito K, Swanson E, Cho N, Ruan DT, Swanson RS, Whang EE.

J Gastrointest Surg. 2010 May;14(5):891-8. doi: 10.1007/s11605-010-1173-3. Epub 2010 Mar 12.

PMID:
20224984
12.
13.

Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors.

Norton JA, Kivlen M, Li M, Schneider D, Chuter T, Jensen RT.

Arch Surg. 2003 Aug;138(8):859-66.

PMID:
12912744
14.

Sporadic nonfunctioning pancreatic neuroendocrine tumors: prognostic significance of incidental diagnosis.

Birnbaum DJ, Gaujoux S, Cherif R, Dokmak S, Fuks D, Couvelard A, Vullierme MP, Ronot M, Ruszniewski P, Belghiti J, Sauvanet A.

Surgery. 2014 Jan;155(1):13-21. doi: 10.1016/j.surg.2013.08.007. Epub 2013 Nov 12.

PMID:
24238123
15.

Lymph node sampling rates and predictors of nodal metastasis in pancreatic neuroendocrine tumor resections: the UCSF experience with 149 patients.

Parekh JR, Wang SC, Bergsland EK, Venook AP, Warren RS, Kim GE, Nakakura EK.

Pancreas. 2012 Aug;41(6):840-4. doi: 10.1097/MPA.0b013e31823cdaa0.

PMID:
22781907
16.

Outcomes of resected nonfunctional pancreatic neuroendocrine tumors: Do size and symptoms matter?

Sallinen V, Haglund C, Seppänen H.

Surgery. 2015 Dec;158(6):1556-63. doi: 10.1016/j.surg.2015.04.035. Epub 2015 Jun 10.

PMID:
26070847
17.

Regional lymphadenectomy is indicated in the surgical treatment of pancreatic neuroendocrine tumors (PNETs).

Hashim YM, Trinkaus KM, Linehan DC, Strasberg SS, Fields RC, Cao D, Hawkins WG.

Ann Surg. 2014 Feb;259(2):197-203. doi: 10.1097/SLA.0000000000000348.

18.

Operative Versus Nonoperative Management of Nonfunctioning Pancreatic Neuroendocrine Tumors.

Zhang IY, Zhao J, Fernandez-Del Castillo C, Braun Y, Razmdjou S, Warshaw AL, Lillemoe KD, Ferrone CR.

J Gastrointest Surg. 2016 Feb;20(2):277-83. doi: 10.1007/s11605-015-3043-5. Epub 2015 Dec 21.

PMID:
26691146
19.

Impact of extent of surgery on survival in patients with small nonfunctional pancreatic neuroendocrine tumors in the United States.

Gratian L, Pura J, Dinan M, Roman S, Reed S, Sosa JA.

Ann Surg Oncol. 2014 Oct;21(11):3515-21. doi: 10.1245/s10434-014-3769-4. Epub 2014 May 20.

20.

Small, nonfunctioning, asymptomatic pancreatic neuroendocrine tumors (PNETs): role for nonoperative management.

Lee LC, Grant CS, Salomao DR, Fletcher JG, Takahashi N, Fidler JL, Levy MJ, Huebner M.

Surgery. 2012 Dec;152(6):965-74. doi: 10.1016/j.surg.2012.08.038. Epub 2012 Oct 24.

PMID:
23102679

Supplemental Content

Support Center